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Abstract
C-Src is infrequently mutated in human cancers but it mediates oncogenic signals of many 
activated growth factor receptors and thus remains a key target for cancer therapy. However, the 
broad function of Src in many cell types and processes requires evaluation of Src-targeted 
therapeutics within a normal developmental and immune-competent environment. In an effort to 
understand the appropriate clinical use of Src inhibitors, we tested a Src inhibitor, SKI-606 
(bosutinib), in the MMTV-PyVmT transgenic mouse model of breast cancer. Tumor formation in 
this model is dependent on the presence of Src, but the necessity of Src kinase activity for tumor 
formation has not been determined. Furthermore, Src inhibitors have not been examined in an 
autochthonous tumor model that permits assessment of effects on different stages of tumor 
progression. Here we show that oral administration of SKI-606 inhibited the phosphorylation of 
Src in mammary tumors, and caused a rapid decrease in the Ezh2 Polycomb group histone H3K27 
methyltransferase and an increase in epithelial organization. SKI-606 prevented the appearance of 
palpable tumors in over 50% of the animals and stopped tumor growth in older animals with 
preexisting tumors. These antitumor effects were accompanied by decreased cellular proliferation, 
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altered tumor blood vessel organization and dramatically increased differentiation to lactational 
and epidermal cell fates. SKI-606 controls the development of mammary tumors by inducing 
differentiation.
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Src; SKI-606; mouse; breast cancer; Ezh2
Introduction
In breast cancer, Src is of particular interest because it is activated by both steroid hormone 
receptors and ErbB family growth factor receptors, and activates transcription factors such 
as STAT3, STAT5 and β-catenin by direct phosphorylation (Kim et al., 2009; Silva and 
Shupnik, 2007). Cellular Src was discovered in 1978 as the cellular counterpart of a viral 
gene, v-src, the transforming agent of Rous sarcoma virus (Spector et al., 1978). This non-
receptor tyrosine kinase belongs to a family of proteins that mediate signaling by a large 
number of growth factor receptors, integrins, G-protein coupled receptors, hormones and 
stress responses implicated in multiple types of cancer and vascular biology (Criscuoli et al., 
2005; Kim et al., 2009; Summy and Gallick, 2006). Src is over-expressed and activated in 
many human cancers, including breast cancer, and activation generally correlates with poor 
prognosis. Nonetheless, biomarkers predictive of a clinical response remain elusive.
The Src inhibitors dasatinib, saracatinib (AZD0530), and SKI-606 (bosutinib) are in Phase II 
clinical development for the treatment of solid tumors of metastatic breast and prostate 
cancer. SKI-606, a multikinase inhibitor originally identified as a Src and Abl kinase 
inhibitor, is effective in vitro on colorectal and breast tumor cells, chronic myelogenous 
leukemia cells and also in multiple xenotransplantation experiments (Boschelli et al., 2001; 
Jallal et al., 2007; Vultur et al., 2008). Src inhibitors generally have subtle effects on tumor 
cells under normal culture conditions (Golas et al., 2005; Vultur et al., 2008). The effects of 
SKI-606 in models of developing breast cancer has not been reported
The many functions of Src and Src family kinases in multiple signaling pathways suggests 
that the effects of inhibiting Src should be integrated into a whole animal context with a 
fully functional immune system (Finn, 2008). The Src-dependent, immunocompetent, 
autochthonous FVB/N-Tg(MMTV-PyVmT)634Mul (MMTV-PyMT) breast cancer mouse 
model is an ideal tool for such a study because it permits the evaluation of both early and 
late stages of luminal type metastatic carcinomas (Guy et al., 1992; Lin et al., 2003). This 
model mimics changes associated human breast cancer progression including up regulation 
of cyclinD1 and HER2, and infiltration of leukocytes. PyMT-induced mammary tumors are 
dependent on multiple signaling molecules, including c-Src, phosphatidylinositol-3-kinase, 
Shc and Insulin/IGF-1 receptors (Ishizawar and Parsons, 2004).
Genetic inactivation of the c-src gene in MMTV-PyMT mice limits the effect of PyMT 
transgene expression to formation of hyperplastic lesions in mammary tissues after a long 
latency period with activated levels of c-Yes, a closely related member of the Src family of 
kinases (Guy et al., 1994). C-Src activation by PyMT is not the sole driver for 
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tumorigenesis, since expressing activated Src under the MMTV-promoter in the absence of 
PyMT leads to defective mammary development and hyperplasia, but not invasive tumor 
formation (Webster et al., 1995). Similarly, when PyMT is mutated to block either SHC or 
PI3-kinase association, only hyperplastic lesions are formed, (Webster et al., 1998) unless 
an angiogenic stimulus such as VEGF is provided (Oshima et al., 2004).
Our studies show that SKI-606 treatment suppressed both early hyperplastic stages of the 
disease and overt tumor development. SKI-606 treatment stopped growth of established 
tumors by inducing dysplastic differentiation of tumor cells and altered vascular 
organization. These responses were accompanied by downregulation of the Polycomb 
repressor complex 2 subunit EZH2. The control of this aggressive model of breast cancer by 
differentiation suggests that different clinical end points might be considered to evaluate 
drugs that control cancer via differentiation rather than cell death.
Results
SKI-606 inhibits cell growth in culture without inducing cell death
Previous studies indicated that treatment with 1 uM SKI-606 significantly reduced 
phosphorylation of the Y418 gatekeeper residue of c-Src in human tumor cells (Golas et al., 
2005; Vultur et al., 2008). To determine whether SKI-606 affected in vitro growth of PyMT-
transformed mammary tumor cells, Py-230 cells were treated with SKI-606 at various 
concentrations. In a 4-day assay, submicromolar concentrations of SKI-606 inhibited Py-230 
cell proliferation (Fig. 1A). However Py-230 cells formed colonies from single cells in the 
presence of up to 750 nM SKI-606 (Fig. 1A), but colony size was significantly reduced (Fig. 
1B), suggesting that SKI-606 inhibited proliferation of Py-230 cells without significant 
cytotoxic effects. Phosphorylation of SrcY418 was inhibited by 1 uM SKI-606 without 
affecting the total amount of Src protein (Fig. 1A, right, lane 3) while 0.1 uM SKI-606 had 
little effect. Y418 phosphorylation is required for full activity (Kmiecik and Shalloway, 
1987) and thus, the extent of Y418 phosphorylation is an estimate of the maximum required 
concentration of a compound that fully inhibits Src.
SKI-606 accumulates in tumor tissue and inhibits Src activity
Previous published data indicated that orally administered SKI-606 was well distributed in 
the tissues of nude mice and accumulated in human tumor xenografts. Analysis of plasma 
obtained from MMTV-PyMT tumor-bearing mice 18 hours after a single oral dose of 
SKI-606 revealed plasma concentrations of 321 ng/ml (604 nM), well above the 
concentration effectively inhibiting Src kinase activity (Boschelli et al., 2001) and well 
within the range required to inhibit breast cancer tumor cell growth and invasion in cell 
culture (Jallal et al., 2007; Vultur et al., 2008) (Fig. 1C). In addition, SKI-606 accumulates 
in PyMT tumors to a concentration of 2477 ng/g of tumor (Fig. 1C). We determined the 
relative levels of active Src in these tumors by monitoring the phosphorylation of Y418 18 
hours following SKI-606 administration. SKI-606 treatment reduced P-Y418 levels in 
PyMT tumors by 75% of the levels observed in tumors from vehicle-treated animals (Fig. 
1D), suggesting that SKI-606 inhibits the intended molecular target.
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SKI-606 suppresses mammary tumor appearance
PyMT expression occurs about four weeks after birth upon mammary gland development at 
sexual maturity. The mammary epithelial tree of MMTV-PyMT adolescent females 
develops a small tumor-like mass beneath the nipple area concurrent with the emergence of 
the normal epithelial branching tubes (Maglione et al., 2001; Neznanov et al., 1999). Next 
focal hyperplastic lesions arise among the normal epithelial structures, which then progress 
to mammary intraepithelial neoplasia (MIN) and later to invasive cancer (Lin et al., 2003; 
Maglione et al., 2001).
Two groups of female MMTV-PyMT mice were administered SKI-606 (150 mg/kg) or 
vehicle by oral gavage at age 30 ± 2 days for up to 45 additional days on a schedule of five 
consecutive daily treatments followed by two days without treatment. All animals tolerated 
SKI-606 administration and SKI-606-treated animals could not be distinguished from the 
control group by weight (Fig. 2). All control animals developed palpable tumors at ages 
between 38 and 55 days (Fig. 2B). No tumors were detected in SKI-606-treated mice until 
an age of 60 days and only half of the treated animals developed obvious tumors by 75 days. 
Upon termination of treatment, only a few SKI-606 treated mice had tumors that could be 
recovered by dissection and none of these animals developed metastases in the lungs. The 
entire mammary glands of animals without grossly apparent malignancies were dissected 
from both groups and compared by weight. Figure 2C shows that SKI-606 treatment 
resulted in less dense mammary tissue than that observed with tissue from vehicle treated 
animals (P=0.002). Histological analysis revealed that mammary glands from SKI-606-
treated animals had large fluid-filled cysts (Fig. 2D-d, 2D-e), containing abundant casein 
protein (Fig. 2D-f). Control tissue contained solid masses of typical MMTV-PyMT tumor 
cells (Fig. 2D-a, 2D-b). Reduced levels of casein were found in the vehicle control tumors 
(Fig. 2D-c) with a less extensive distribution. These results revealed SKI-606's remarkable 
anti-tumor efficacy with less than half of the animals developing overt, discrete tumors in 
this highly aggressive tumor model. Furthermore, mammary glands from SKI-606-treated 
mice had dysplastic but more differentiated cystic structures containing milk protein.
Tumors from SKI-606 treated mice are differentiated
To test the effect of SKI-606 treatment on developed mammary tumors, animals with tumor 
sizes of 0.6 to 1 cm in diameter were treated 14 consecutive days. Tumors of control animals 
continued to grow steadily with increasing variability in tumor size over time (Fig. 3A). In 
contrast, tumors in SKI-606-treated mice did not increase in size. After two weeks of 
treatment, the excised tumor weights were approximately half that of tumors from the 
control group (Fig. 3B). Staining of proliferative cell nuclear antigen (PCNA) revealed that 
tumors from SKI-606-treated mice were not as mitotically active (Fig. 3C). Histological 
examination showed the typical high nuclear density and undifferentiated state of PyMT 
tumors (Fig. 3-a, 3D-b, 3D-g). By contrast, SKI-606-treated tumors were heterogeneous 
with areas of higher nuclear density mixed with more epithelial glandular and papillary type 
structures (Fig. 3D-c, 3D-d). Some tumors had cysts lined by stratified squamous epithelium 
that produced copious laminated keratin debris. This type of differentiation has been 
previously observed with some types of MMTV-PyMT crosses and in Wnt-induced 
mammary tumors (Miyoshi et al., 2002; Rosner et al., 2002). Cystic areas of the tumors also 
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contained abundant beta-casein protein (Figure 3D-h). Of six animals of each group 
inspected for lung metastases, five of each group were found to have metastases. The 2-
week SKI-606 treatment did not change the average of three metastases per lung per group, 
which likely existed before treatment start (Kouros-Mehr et al., 2008). The sizes of the 
metastases were similar in both groups. The small size of most of the metastases prevented a 
definitive conclusion concerning differences in differentiation state.
PyMT tumors develop as expansions of keratin 8 (K8)-positive luminal epithelial cells lined 
by some keratin 14 (K14)-positive myoepithelial cells at early stages (Fig. 4A). The cystic 
structures induced by SKI-606 treatment contained both luminal K8-positive epithelial cells 
and K14-positive basal-like cells. These structures of SKI-606-treated tumors differed from 
normal mammary glands by occasional penetration of the luminal layer with K14-positive 
cells (Supplemental data, Fig. S2A) and by the lack of smooth muscle actin staining in the 
K14 cell layer (Supplemental data, Fig. S2C). This differentiated state was not accompanied 
by an increase in apoptosis assessed by DNA end labeling (Fig. S2B). Furthermore, ER was 
found associated with the highly proliferative outer rim of tumors and within stromal cells 
(Fig. S2D). The nuclear ER at the outer margin of tumor masses and within many of the 
organized epithelia was not diminished by SKI-606 treatment (Fig. S2D).
SKI-606 treatment induces remodeling of mammary tumor vasculature
To determine the impact of SKI-606 on PyMT tumor vascularity, we stained tumor sections 
with anti-CD31. The vascular network of the vehicle-treated tumors displayed a chaotic 
organization (Fig. 4C, left). Control tumor vessels were largely dilated and the endothelium 
was thick or extended resulting in severe vessel deformation. These vessel abnormalities are 
hallmarks of the tumor vasculature (Cheung et al., 1997; Jain, 2005). SKI-606 treatment 
resulted in significant remodeling of the tumor vasculature after 14 days of treatment. The 
vascular network of SKI-606-treated mammary tumors exhibited reduced dilation (Fig. 4C, 
D) and a thinner vessel endothelium (Fig. 4C, right), minimizing vessel deformation. 
Furthermore, the vessels in the SKI-606-treated tumors appeared to be more evenly 
distributed than those in control tumors (Fig. 4C). While SKI-606 induced significant 
structural remodeling of the vessels, it did not affect the overall tumor vessel density (Fig. 
4D, right). SKI-606 treatment may directly or indirectly induce normalization of the tumor 
vasculature as observed in the vascular normalization phenomenon induced by VEGF 
blockade-based antiangiogenic therapies (Jain, 2005).
Gene expression changes associated with SKI-606 treatment
The RNAs of eight tumors each from SKI-606- and vehicle-treated mice each were analyzed 
for gene expression changes on two different array platforms (Illumina bead arrays, 
Affymetrix arrays) to identify the most robust gene expression changes. Data are available 
from the GEO accession numbers GSE20921 and GSE22150. Given the histological 
variation, the list of genes that were significantly changed in both arrays was small (Table 
S1). Comparison of the 34 genes altered by SKI-606 treatment to other array results resulted 
in identifying multiple studies with similar gene expression changes (Table S2). In four 
examples, SKI-606-induced genes were decreased in cancer cells. Increased expression of 
these genes in SKI-606 treated tumors is consistent with reversing the cancer phenotype. 
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Twelve of the 34 SKI-606-induced genes were increased in lactating normal mammary 
gland. These results are consistent with the increased casein level and increased epithelial 
differentiation of SKI-606-treated tumors. Examination of keratin gene expression in 
individual tumors and their corresponding histological appearance revealed that increased 
expression of keratin genes was associated with only three of the eight tumors (Fig. 5A and 
B). However, each of those tumors with increased K5, K7, K14 and K17 also had areas of 
epidermal-like differentiation (Fig. 5C, tumors 737, 787 and 698). These results suggest that 
PyMT tumors do not respond uniformly to SKI-606 but rather may adopt distinct 
differentiated fates or respond asynchronously depending on their particular 
microenvironment.
Western blot analysis of four of six serum samples from tumor-bearing animals treated with 
SKI-606 for 14 days had elevated casein protein levels while none of the six samples from 
tumor-bearing control mice showed similar casein levels (Supplemental data, Fig. S5). The 
casein signal was comparable to serum levels found in lactating mothers (Supplementary 
data, Fig. S5B, lanes 8, 9). These results suggest a blood test may provide information about 
the differentiation response.
SKI-606 treatment reduces Ezh2 expression
The Ezh2 polycomb group protein expression is elevated in aggressive human breast cancers 
(Kleer et al., 2003) and increased expression is associated with reduced E-cadherin levels 
(Cao et al., 2008). SKI-606 treatment increases E-cadherin stability in colorectal tumor cells 
and E-cadherin localization at the plasma membrane in several cell types (Jallal et al., 2007; 
Vultur et al., 2008) (Coluccia et al., 2006). Given these relationships, and the profound 
responses in the SKI-606-treated mice, we examined the effects of SKI-606 on Ezh2 levels.
Ezh2 levels of tumors 18 hours after a single dose of SKI-606 were measured by 
immunoblot analysis. Ezh2 levels were reduced by approximately 50% in SKI-606-treated 
samples (Fig. 6A, 6B). In addition, RT-PCR analysis of RNA from tumors excised from 
mice 8 hours after SKI-606 administration revealed a 50% reduction of Ezh2 mRNA (Fig. 
6B). E-cadherin mRNA levels increased after a single treatment with SKI-606 (Fig. 6B). 
Immunohistochemical analysis revealed high and nearly uniform expression of Ezh2 in the 
MMTV-PyMT tumor lobes. This expression was decreased in tumors from animals treated 
with SKI-606 just once (Fig. 6C-a), (Supplementary data, Fig. S4). Furthermore, decreased 
Ezh2-staining appeared to correlate with portions of the tumors that had adopted a more 
epithelial morphology (Figure 6C-c, 6C-d, arrows). In tumors treated for 14 days, Ezh2 was 
greatly diminished (Fig. 4B; supplementary Fig. S3). E-cadherin staining was very strong in 
the differentiated epithelial cysts formed following 14 days of treatment (Fig. 4B) 
(Supplementary Fig. S3). In tumor samples with epidermal differentiation, Ezh2 was 
localized in the presumptive proliferative cells surrounding the focal keratin differentiation. 
E-cadherin localization appeared adjacent to Ezh2 in these areas (Supplementary data, Fig. 
S3, sample 2241). This organization of Ezh2 and E-cadherin is similar to that observed 
during normal epidermal development (Ezhkova et al., 2009). These data show that a key 
developmental regulatory protein decreases rapidly after SKI-606 exposure and its loss is 
associated with increased E-cadherin RNA and more organized epithelium.
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Discussion
Treatment of adolescent MMTV-PyMT females for four weeks effectively prevented 
palpable tumor formation in half of the SKI-606 treated animals. Instead of residual solid 
tumors, distended, dysplastic mammary cysts with accumulated casein protein filled the fat 
pads. The differentiation-inducing effect of SKI-606 was most dramatically demonstrated by 
the 2-week treatment of tumor-bearing animals. This resulted in enrichment of organized 
K14-positive basal epithelia juxtaposed with luminal epithelial cells in cystic structures, the 
accumulation of milk protein and sporadic epidermal differentiation. Strikingly similar 
observations of cystic buildup of milk proteins were reported for Src null mice, which were 
ascribed to a defect in secretory activation during pregnancy (Watkin et al., 2008).
The relatively small list of differentially expressed genes in SKI-606 treated tumors is likely 
because of the variation of the differentiation of individual tumors that decreased the 
probability of passing multiple statistical thresholds. Genes whose expression was increased 
in all SKI-606-treated tumors overlap significantly with genes increased during lactation 
(Rudolph et al., 2007) and repressed in mouse transgenic tumors caused by c-Myc, SV40 T 
antigen and ETV6-NTRK3 (Bild et al., 2006; Klein et al., 2005; Li et al., 2007) and human 
breast cancer cell lines (Klein et al., 2005). These results suggest that the SKI-606 induced 
differentiation reflects the reversal of a common transcriptional response to oncogene 
transformation. The induction of differentiation by SKI-606 may be related to the function 
of Src in ER signaling (Ishizawar and Parsons, 2004). Cross talk between ER and Src is well 
documented and may include effects on the nuclear localization of ER. Src null mice have 
defects in mammary gland development and ER signaling (Kim et al., 2005b). While we 
found no differences in the cellular distribution of ER in both tumor cells or in stromal cells 
of mice treated with SKI-606, alterations in ER activity may still contribute to the diverse 
differentiation responses observed.
Differentiation of SKI-606-treated PyMT tumors was associated with changes in vascular 
organization, although not vascular density. Src is involved in the production of VEGF 
(Mukhopadhyay et al., 1995) and Src is activated by VEGF receptors (Eliceiri et al., 1999). 
Significantly, the observed changes in vascular organization after SKI-606 treatment are 
consistent with normalization of the more permeable and tortuous vessels found in these 
tumors (Cheung et al., 1997). SKI-606 treatment reduces tumor cell extravasation (Weis et 
al., 2004) at least in part by strengthening VE-cadherin (cadherin 5) and beta-catenin 
interaction. SKI-606 was also effective in models for ischemic stroke where VEGF-induced 
vascular leakage mediated by Src activation is believed to play a dominant role in disease 
etiology. These observations suggest that Src inhibition by SKI-606 contributes to tumor 
vascular normalization. While SKI-606 was originally developed as a Src inhibitor, 
subsequent studies indicated that it targets multiple kinases including Abl kinases (Remsing 
Rix et al., 2009). At the RNA level, Lck, Egfr and Csk are expressed at detectable levels in 
PyMT tumors and are reported to have SKI-606 IC50 of 100 nM or less (Remsing Rix et al. 
2009). However, the observed biological responses to SKI-606 treatment are consistent with 
existing knowledge of the roles of Src in angiogenesis, tumor cell survival, proliferation and 
motility (Finn, 2008). Src inhibition alone may be responsible for a large part of the 
observed biological effect on these tumors.
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Apoptosis outside of obviously necrotic areas was not increased significantly in tumors 
treated for either 18 hours (data not shown) or two weeks. Thus, the response of tumor cells 
to SKI-606 appears to be decreased proliferation but not elevated cell death. Within tumor 
cells, Src binds to and mediates the oncogenic signaling of Polyoma middle T antigen 
(Courtneidge and Smith, 1983). While the presence of Src is required for PyMT-induced 
tumors to form in the mammary gland (Guy et al., 1994), deleting Src is not equivalent to 
inhibiting its kinase activity, as demonstrated by partial restoration of osteoclast function by 
expression of catalytically inactive Src in Src-deficient osteoclasts (Schwartzberg et al., 
1997). SKI-606 treatment for 4 weeks resembles the result of genetically inactivating Src. 
This is consistent with Src inhibition being an important mediator of the effects of SKI-606.
PyMT activates both Src and PI3 kinase pathways, much like the combination of ErbB2 and 
ErbB3 signaling. Src is also activated by ErbB2 receptor signaling (Muthuswamy et al., 
1994), directly associates with the same receptor (Kim et al., 2005a) and facilitates the 
heterodimerization of ErbB2 and ErbB3 (Ishizawar et al., 2007). Thus, SKI-606 might be 
expected to have similar effects on ErbB2-driven mammary tumors as those observed here 
for PyMT-driven tumors.
Ezh2 is a core component of the Polycomb Repressive Complex 2 (PRC2), that mediates 
gene repression by methylating lysine 27 on histone H3 and recruiting histone deacetylase 
(Bracken and Helin, 2009). PRC2 may maintain pluripotency by silencing developmental 
regulators that drive differentiation (Lee et al., 2006). Poorly differentiated human tumors 
show preferential repression of PRC2-regulated genes and this expression pattern is 
associated with poor clinical outcome. There is a strong correlation between elevated Ezh2 
levels and poorly differentiated breast carcinomas (Kleer et al., 2003). Deregulated 
expression of Ezh2 and its downstream target genes may play a critical role in maintaining 
the arrested differentiation phenotype observed in aggressive tumors.
Treatment of MMTV-PyMT tumors with SKI-606 resulted in a rapid reduction in Ezh2 
protein, and a modest increase in E-cadherin mRNA, as might be expected from the 
transcriptional inhibition of the E-cadherin promoter by Ezh2, (Cao et al., 2008). However, 
E-cadherin protein and RNA are expressed within PyMT tumor cells suggesting that EZH2 
is not sufficient to silence E-cadherin in this system. SKI-606 may alter Ezh2 levels 
indirectly through miR-101; a group of microRNAs that have been shown to negatively 
regulate Ezh2 levels (Varambally et al., 2008). The relatively rapid inhibition of Ezh2 
expression following SKI-606 treatment is consistent with a functional and early role of 
Ezh2 rather than only a reflection of the later differentiated state of treated tumors. This is 
not likely due only to an anti-proliferative effect because a single treatment with SKI-606 
for 18 hours did not result in a significant decrease in PCNA labeling index (not shown), 
even though Ezh2 protein was clearly decreased. Over-expression of Ezh2 in the mouse 
mammary epithelium leads to intraductal hyperplasia and delayed involution (Li et al., 
2009). Similarly, MMTV-driven expression of activated Src causes mammary hyperplasia 
and arrested lobuloalveolar development (Webster et al., 1995), suggesting that both 
proteins may cooperate to restrict the cell fates and maintain the undifferentiated cellular 
phenotypes that are common in aggressive breast cancers. The restriction of MMTV-PyMT 
tumors by SKI-606 induced differentiation may be mediated by both tumor and host cell 
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responses. The restriction of mammary tumor progression by induced differentiation is a 
relatively rare example that stimulates consideration of differentiation therapy. It will be of 
great interest to determine the link between Src inhibition and Ezh2 expression in 
developing breast cancer.
Materials and Methods
Antibodies
The antibodies used were: keratin 8 (TROMA1, Developmental Studies Hybridoma Bank, 
University of Iowa); keratin 14 (Covance, PRB-155P); CD31 (Pharmingen, 01951D, BD 
Bioscience), PCNA (Sigma, P8825), smooth muscle actin (Sigma, C6198), EZH2 (6A10, 
Novocastra and AC22, Cell Signaling). E-Cadherin, Clone 24E10, (Cell Signaling 
Technologies) and Alexa 488 donkey anti-rabbit IgG (Molecular Probes A21206), Alexa 
568 goat anti rat IgG (Invitrogen 11077), HRP anti-mouse IgG (DAKO Envision system) 
and anti-rabbit IgG (Vector ImmPRESS).
The Py-230 cell line was isolated from a MMTV-PyMT tumor by Dr. Leslie Ellies and 
grown in F12K media (Mediatech), supplemented with 5% fetal bovine serum and MITO 
growth factor supplement (Fisher CB50006). Cell numbers were determined by imaging 
methanol-fixed cells grown for 4 days in 96-well plate stained with DAPI using the 
Beckman IC-100 imagining equipment and Cytoshop software. Data of nine images per well 
and triplicate wells were used to calculate total cell numbers.
Animal procedures
The transgenic MMTV-PyMT mouse on the FVB/N genetic background was obtained from 
Dr. William Muller (Guy et al., 1992). Genotypes were determined previously described 
(Man et al., 2003). Tumor analysis was performed as previously described (Liu et al., 2005; 
Neznanov et al., 1999). SKI-606 was formulated in 0.5% methocellulose and 0.4% Tween 
80 and administered by oral gavage at 150 mg/kg. Hyperplastic areas of whole mounted 
mammary glands were measured from images converted to gray scale. Total pixel areas of 
threshold images were measured using Image J software. Statistical tests were performed 
within the Prism® suite of tests. SKI-606 levels in plasma were determined as previously 
described (Boschelli et al., 2001).
Histology
Apoptosis was detected using terminal deoxynucleotidyl transferase-mediated dUTP nick 
end-labeling of hydrolyzed nuclear DNA, (ApopTag, Millipore Co). Antigen retrieval was 
performed in citrate buffer, pH 6 on zinc-formalin (Z-fix, Anatech, Battle Creek MI) fixed 
paraffin embedded tissues. K8, K14, smooth muscle actin and CD31 were detected with 
acetone-fixed, sucrose infused, OCT embedded, frozen sections. Volocity software 
(Improvision) was used to determine blood vessel area, perimeter, and density. Four tumors 
were analyzed for each group using seven random areas from each tumor section. Over 
3,000 tumor blood vessels were individually analyzed in total for each group.
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Protein and RNA analysis
Immunoprecipitation and western blot analysis was performed as described (Jallal et al., 
2007). Quantitative real-time PCR was performed with FAM-labeled TaqMan probe sets 
specific for mEzh2 (Mm00468464_m1) or beta-Actin (Mm01205647_g1) from Applied 
Biosystems. Cdh1 RNA was independently measured using methods that were previously 
described (Galang et al., 2004).
Gene Expression Array analysis
RNA was analyzed with Illumina MouseRef-8 BeadChips using the manufacturer's 
BeadArray Reader and Scanner and BeadStudio software. In addition, an additional set of 
tumors from control and test groups was analyzed using Affymetrix chips and procedures. 
Data analysis was done in three stages. First, expression intensities were calculated for each 
gene probed on the array for all hybridizations (26 in total) using Illumina's Beadstudio #1 
software. Second, intensity values were quality controlled and normalized: quality control 
was carried out by using the Illumina Beadstudio detection P-value set to be 0.1 as a cutoff. 
This removed genes that were not detected. All the arrays were then normalized using the 
normalize quantiles routine from the Affymetrix package in Bioconductor. These 
normalized data were imported into GeneSpring and analyzed for differentially expressed 
genes. The groups of biological replicates were described to the software, and significantly 
differentially expressed genes were determined based on t-tests and fold difference changes 
in expression level. Primary data is deposited in GEO database under accession numbers: 
GSE20921 and GSE22150.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
SKI-606 effects on Py-230 cells and Src phosphorylation. A, concentration dependence of 
SKI-606 on cell growth and cloning efficiency of the Py-230 mammary tumor cell line. 
Immunoprecipitation and western blot analysis show the effect of SKI-606 on 
phosphorylated Src in Py-230 cells. B, morphology of Py-230 clones in control or 500 nM 
SKI-606. C, SKI-606 levels in tumors and plasma 18 hours after treatment of tumor-bearing 
MMTV-PyMT females. D, phosphorylation state of Src in tumors from vehicle and 
SKI-606-treated animals. Representative western blot images of Src signals of tumors from 
animals receiving the vehicle or SKI-606. Bar graph shows the mean and standard deviation 
of signals of Src phosphorylated on tyrosine 418 (PY418 Src) normalized to total Src.
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Figure 2. 
Suppression of tumor appearance by SKI-606. A, average weight of animals treated with 
SKI-606 or vehicle. Error bars indicate standard deviations of binned ages as indicated. B, 
tumor incidence. The P value was calculated by the log rank test. C, weight of tumor-free 
mammary gland. The fourth inguinal mammary glands that had no discrete tumor mass were 
excised and weighed. D, sections of mammary tumors (a, b, c) from control mice and of the 
mammary glands of SKI-606-treated mice (d, e, f) were either stained with HE (a, b, d, e) or 
with antibody to beta-casein (red) (c, f) and DAPI (blue).
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Figure 3. 
Effect of SKI-606 on fully developed tumors. A, Tumor size was measured at the indicated 
time of treatment starting with tumors of approximately 1 cm in diameter. The average and 
standard deviations are shown for groups binned for elapsed time of treatment for clarity. 
Linear regression analysis of all data indicated an extremely significant difference in the 
slopes of the two lines. Both slopes were also judged differ from zero. B, average weight of 
excised tumors after 14 days of treatment. C, proliferative cell nuclear antigen (PCNA) was 
detected by antibody staining of tumor sections. Average and standard deviation of the 
nuclei fraction stained positive for PCNA. D, increased diversity of tumor histology after 
treatment with SKI-606 for 14 days. Control tumors are shown in D-a, D-b and D-g. Tumors 
from SKI-606-treated mice are shown in panels D-c, D-d, D-e, D-f and D-h. Panels D-a 
through D-f show sections stained with hematoxylin and eosin. Panels D-g and D-h show 
staining for beta-casein (red) and nuclei (blue). Arrows in panels D-e and D-f, point to 
keratinizing epithelium.
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Figure 4. 
Keratin, Ezh2 and CD31 expression in tumors treated with SKI-606 for 14 days. Luminal 
epithelial lineages (K8, red) and basal-like epithelia (K14, green) were visualized in sections 
of tumors of mice treated with vehicle (A-a) or SKI606. (A-b). B, localization of Ezh2 and 
E-cadherin in tumors. Lower panels show decreased Ezh2 expression of SKI-606-treated 
tumors. C, CD31 (red) staining of tumor sections. SKI-606-treated tumor (right) has more 
organized and regular spacing. D, image analysis reveals length of vessel perimeter (left), 
endothelium area of vessel (middle), by t-test and vessel density (right). *P < 0.001, ** P = 
0.32 calculated by T-test. Average values and standard errors are indicated.
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Figure 5. 
Variability of differentiation induced by SKI-606. Bisected tumors were fixed, sectioned and 
stained with HE. RNA was isolated from half of the tumor and analyzed by either Illumina 
or Affymetrix array methods. A, normalized individual RNA sample results for keratin 
RNAs. The fold increase in expression is relative to the average of four control PyMT tumor 
RNA samples. Tumors are identified by the indicated animal number with appended letters 
for multiple tumors isolated from individual animals. B, keratin RNAs detected by 
Affymetrix array methods of the indicated tumors. C, histological detection of epidermal 
keratin differentiation. Epidermal differentiation was noted in tumors 737, 787 and 698 
which corresponds to increased keratin 5, 14 and 17 RNA detected by both arrays.
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Figure 6. 
Suppression of Ezh2 by SKI-606 treatment. MMTV-PyMT tumor-bearing animals were 
treated once with SKI-606 and analyzed 18 hour later. A, filter image of Ezh2 and actin 
signals. B, mean and standard deviation of Ezh2 protein signals normalized to actin. Values 
represent the average and standard deviation of six values from three treated and control 
tumors. Ezh2 and Cdh1 RNAs were measured by Q-rtPCR normalized to actin or 
cyclophilin RNA levels. Bars represent the mean and standard deviation of relative RNA 
from three or four tumors each. P value represents the results of T-test. C, 
immunohistochemical localization of Ezh2 and E-cadherin in sections of tumors treated with 
vehicle or SKI-606. Brown color reveals reaction with the indicated antibodies. In C-c and 
C-d solid tumor areas reactive with the Ezh2 antibody are indicated with drawn lines. Areas 
not reactive with Ezh2 appear in greater epithelial organization (arrows). The digitally 
magnified inset in panel C-c has the brown color replaced with red for clarity of boundary 
between a reactive and non-reactive portion of the tumor. Insets in panels C-a, C-b and C-d 
are digitally magnified to reveal the nuclear localization of Ezh2 and the junctional location 
of E-cadherin antibody reaction.
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